FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360992719> ?p ?o ?g. }

• W4360992719 endingPage "2723" @default.
• W4360992719 startingPage "2718" @default.
• W4360992719 abstract "Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The REMoDL-B phase III adaptive trial compared rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) versus R-CHOP + bortezomib (RB-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL), stratified by molecular subtype. Primary analysis at a median follow-up of 30 months found no effect of bortezomib on progression-free survival (PFS) or overall survival (OS). Retrospective analysis using a gene expression-based classifier identified a molecular high-grade (MHG) group with worse outcomes. We present an updated analysis for patients successfully classified by the gene expression profile (GEP). Eligible patients were age older than 18 years with untreated DLBCL, fit enough for full-dose chemotherapy, and with adequate biopsies for GEP. Of 1,077 patients registered, 801 were identified with Activated B-Cell (ABC), Germinal Center B-cell, or MHG lymphoma. At a median follow-up of 64 months, there was no overall benefit of bortezomib on PFS or OS (5-year PFS hazard ratio [HR], 0.81; P = .085; OS HR, 0.86; P = .32). However, improved PFS and OS were seen in ABC lymphomas after RB-CHOP: 5-year OS 67% with R-CHOP versus 80% with RB-CHOP (HR, 0.58; 95% CI, 0.35 to 0.95; P = .032). Five-year PFS was higher in MHG lymphomas: 29% versus 55% (HR, 0.46; 95% CI, 0.26 to 0.84). Patients with ABC and MHG DLBCL may benefit from the addition of bortezomib to R-CHOP in initial therapy." @default.
• W4360992719 created "2023-03-30" @default.
• W4360992719 creator A5002852999 @default.
• W4360992719 creator A5006217579 @default.
• W4360992719 creator A5007119947 @default.
• W4360992719 creator A5018515767 @default.
• W4360992719 creator A5021965002 @default.
• W4360992719 creator A5022624109 @default.
• W4360992719 creator A5024619109 @default.
• W4360992719 creator A5032833705 @default.
• W4360992719 creator A5039150497 @default.
• W4360992719 creator A5040855579 @default.
• W4360992719 creator A5053549915 @default.
• W4360992719 creator A5055527227 @default.
• W4360992719 creator A5055535893 @default.
• W4360992719 creator A5059813462 @default.
• W4360992719 creator A5063787927 @default.
• W4360992719 creator A5069477380 @default.
• W4360992719 creator A5073165908 @default.
• W4360992719 creator A5074839524 @default.
• W4360992719 creator A5082144670 @default.
• W4360992719 creator A5082248258 @default.
• W4360992719 creator A5084659683 @default.
• W4360992719 creator A5086199896 @default.
• W4360992719 creator A5091115060 @default.
• W4360992719 date "2023-05-20" @default.
• W4360992719 modified "2023-10-17" @default.
• W4360992719 title "Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up" @default.
• W4360992719 cites W1094999820 @default.
• W4360992719 cites W1977163745 @default.
• W4360992719 cites W2147246240 @default.
• W4360992719 cites W2797584152 @default.
• W4360992719 cites W2801763724 @default.
• W4360992719 cites W2902375153 @default.
• W4360992719 cites W2923453543 @default.
• W4360992719 cites W2928384177 @default.
• W4360992719 cites W3016044607 @default.
• W4360992719 cites W3132205831 @default.
• W4360992719 cites W3195024161 @default.
• W4360992719 doi "https://doi.org/10.1200/jco.23.00033" @default.
• W4360992719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36972491" @default.
• W4360992719 hasPublicationYear "2023" @default.
• W4360992719 type Work @default.
• W4360992719 citedByCount "4" @default.
• W4360992719 countsByYear W43609927192022 @default.
• W4360992719 countsByYear W43609927192023 @default.
• W4360992719 crossrefType "journal-article" @default.
• W4360992719 hasAuthorship W4360992719A5002852999 @default.
• W4360992719 hasAuthorship W4360992719A5006217579 @default.
• W4360992719 hasAuthorship W4360992719A5007119947 @default.
• W4360992719 hasAuthorship W4360992719A5018515767 @default.
• W4360992719 hasAuthorship W4360992719A5021965002 @default.
• W4360992719 hasAuthorship W4360992719A5022624109 @default.
• W4360992719 hasAuthorship W4360992719A5024619109 @default.
• W4360992719 hasAuthorship W4360992719A5032833705 @default.
• W4360992719 hasAuthorship W4360992719A5039150497 @default.
• W4360992719 hasAuthorship W4360992719A5040855579 @default.
• W4360992719 hasAuthorship W4360992719A5053549915 @default.
• W4360992719 hasAuthorship W4360992719A5055527227 @default.
• W4360992719 hasAuthorship W4360992719A5055535893 @default.
• W4360992719 hasAuthorship W4360992719A5059813462 @default.
• W4360992719 hasAuthorship W4360992719A5063787927 @default.
• W4360992719 hasAuthorship W4360992719A5069477380 @default.
• W4360992719 hasAuthorship W4360992719A5073165908 @default.
• W4360992719 hasAuthorship W4360992719A5074839524 @default.
• W4360992719 hasAuthorship W4360992719A5082144670 @default.
• W4360992719 hasAuthorship W4360992719A5082248258 @default.
• W4360992719 hasAuthorship W4360992719A5084659683 @default.
• W4360992719 hasAuthorship W4360992719A5086199896 @default.
• W4360992719 hasAuthorship W4360992719A5091115060 @default.
• W4360992719 hasBestOaLocation W43609927191 @default.
• W4360992719 hasConcept C126322002 @default.
• W4360992719 hasConcept C143998085 @default.
• W4360992719 hasConcept C203092338 @default.
• W4360992719 hasConcept C207103383 @default.
• W4360992719 hasConcept C2776364478 @default.
• W4360992719 hasConcept C2776694085 @default.
• W4360992719 hasConcept C2776755627 @default.
• W4360992719 hasConcept C2777478702 @default.
• W4360992719 hasConcept C2778476033 @default.
• W4360992719 hasConcept C2778559949 @default.
• W4360992719 hasConcept C2779338263 @default.
• W4360992719 hasConcept C2779429289 @default.
• W4360992719 hasConcept C2779725641 @default.
• W4360992719 hasConcept C2780653079 @default.
• W4360992719 hasConcept C2780739268 @default.
• W4360992719 hasConcept C44249647 @default.
• W4360992719 hasConcept C535046627 @default.
• W4360992719 hasConcept C71924100 @default.
• W4360992719 hasConceptScore W4360992719C126322002 @default.
• W4360992719 hasConceptScore W4360992719C143998085 @default.
• W4360992719 hasConceptScore W4360992719C203092338 @default.
• W4360992719 hasConceptScore W4360992719C207103383 @default.
• W4360992719 hasConceptScore W4360992719C2776364478 @default.
• W4360992719 hasConceptScore W4360992719C2776694085 @default.
• W4360992719 hasConceptScore W4360992719C2776755627 @default.
• W4360992719 hasConceptScore W4360992719C2777478702 @default.
• W4360992719 hasConceptScore W4360992719C2778476033 @default.

• next